3-(3-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-(3-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one
• 英文别名: 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone；3-(3-Fluoro-phenyl)-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one；4-(3-fluorophenyl)-3-(4-methylsulfonylphenyl)-2H-furan-5-one
• 化学式: C₁₇H₁₃FO₄S
• 分子量: 332.352
• InChiKey: KZNGNTKISMAXAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (2Z)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol
  参考文献：
  名称：

  WO2006/44230

  摘要：

  公开号：

文献信息

• Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors
  申请人：Lockwood Samuel F.

  公开号：US20080293679A1

  公开（公告）日：2008-11-27

  Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.

  向正在接受COX-2抑制剂治疗的受试者施用类胡萝卜素，特别是黄质类胡萝卜素，或者是天然类胡萝卜素的类似物或衍生物，如虾青素、叶黄素、玉米黄质、莱科黄素、莱科菲或番茄红素，可能会减少与使用COX-2选择性抑制剂药物相关的不良副作用的至少一部分。这些类胡萝卜素，或者是其类似物或衍生物，可以在受试者开始接受COX-2选择性抑制剂药物治疗之前、同时或之后进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物治疗同时进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物组合在一起制成药物制剂，也可以单独施用。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者血清和血浆细胞膜中低密度脂蛋白和其他脂质的过氧化。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者发生有害的临床心血管事件的几率。
• Tyrosine kinase inhibitors
  申请人：——

  公开号：US20030100567A1

  公开（公告）日：2003-05-29

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号传导的化合物，包含这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和情况的方法，例如在哺乳动物中的血管生成、癌症、肿瘤生长、动脉粥样硬化、年龄相关性黄斑变性、糖尿病性视网膜病变、炎症性疾病等。
• Method of treating cancer
  申请人：——

  公开号：US20020042375A1

  公开（公告）日：2002-04-11

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and an NSAID compound, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and an NSAID compound. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种NSAID化合物的组合治疗癌症的方法，该方法包括向所述哺乳动物施用至少两种治疗剂量，所述治疗剂量选自一组包括一种PSA共轭物和一种NSAID化合物，所述治疗剂量可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2003011836A1

  公开（公告）日：2003-02-13

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号转导的化合物，包含这些化合物的组合物，以及使用它们治疗哺乳动物的酪氨酸激酶依赖性疾病和状况，例如血管生成、癌症、肿瘤生长、动脉硬化、年龄相关性黄斑变性、糖尿病性视网膜病变、炎症性疾病等的方法。
• Phenyl heterocycles as cyclooxygenase-2 inhibitors
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0822190A1

  公开（公告）日：1998-02-04

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  该发明涵盖了一种新的化合物I式，该化合物对于治疗环氧合酶-2介导的疾病具有用处。该发明还涵盖了某些药物组合物，用于治疗环氧合酶-2介导的疾病，该组合物包括I式化合物。